Bill Lake, a retired engineer from Battersea, Ontario, thought his time was limited when doctors diagnosed him with incurable colon cancer in 2022. Given less than a year to live, he began checking items off a grim bucket list. Then came the treatment that changed everything: Keytruda, an immunotherapy drug that has transformed cancer care while simultaneously putting unprecedented pressure on Canada’s health-care budgets.
The medication worked miracles for Lake, who returned to his beloved beekeeping and celebrated his remission nearly two years later. But Keytruda’s success comes at a steep price—not just for patients, but for the entire public health system. With one in every ten dollars spent on cancer treatments in Canada now going toward this single drug, experts warn the system faces an unsustainable financial crisis.
A Medical Revolution at a Record Price
Approved by Health Canada in 2015, Keytruda (pembrolizumab) represents a paradigm shift in oncology. Unlike chemotherapy that directly attacks cancer cells, the drug works by releasing the brakes on the immune system, enabling the body to fight malignancy itself. Its impact has been revolutionary: stage four melanoma patients who once faced death within a year now enjoy prospects of decade-long survival.
The drug’s portfolio has expanded dramatically, gaining approval for 35 different cancer indications including lung, kidney, breast, gastric and endometrial cancers. This expansion means thousands more patients could potentially benefit annually. Yet each year of treatment carries a list price of approximately $150,000 per patient, creating a fiscal burden that grows exponentially with each new approval.
In 2023 alone, Canada spent nearly $800 million on Keytruda, making it the nation’s single largest hospital drug expense. Dr. Christopher Booth, an oncologist at Queen’s University, explains the gravity: “One out of every $10 spent on cancer hospital treatments is going toward this drug. For people who manage health systems, those numbers have to be concerning.”
The Hidden Economics Behind the Price Tag
Keytruda isn’t just expensive—it’s the world’s top-selling pharmaceutical, generating over $30 billion in US sales last year alone. Merck & Co., the New Jersey-based manufacturer, employs sophisticated strategies to maintain these towering revenues. According to a Star/ICIJ investigation, the company uses patent manipulation, secretive pricing negotiations and aggressive lobbying to keep prices artificially high across multiple markets.
The disparity is staggering: a 100mg vial costs $850 in Indonesia but $6,015 in the United States. Canada’s list price stands at $4,400 CAD per vial. While Canadians do secure substantial discounts through confidential negotiations, the starting point remains problematic. Mina Tadrous, a pharmaceutical policy researcher at the University of Toronto, notes that list prices are “arbitrary” and based primarily on desired profit margins rather than development costs.
These opaque negotiations benefit pharmaceutical companies while leaving the public in the dark. “You hope in the back-and-forth that they can end up somewhere in the middle,” Tadrous explains, describing the complex rebate structures that determine final prices. “Then that price is locked up in a vault and kept secret from everybody.” Despite securing over $5 billion in discounts through the pan-Canadian Pharmaceutical Alliance, critics argue the system remains fundamentally flawed when starting prices are already excessive.
Canada’s Bold Move Against Fixed Dosing
In an unprecedented challenge to pharmaceutical industry practices, Canada has pushed back against Merck’s recommended dosing guidelines. While the manufacturer advocates for a fixed 200mg dose for all adult patients, Canada adopted weight-based dosing—a strategy that allows many patients to receive lower, more proportional amounts.
This decision stems from Merck’s own clinical evidence showing the drug’s safety and efficacy with weight-based administration. The company later shifted to fixed dosing, likely to maximise profits, according to Dr. Booth. “If you step back and look at the financial responsibilities of a corporation, it’s to generate the largest profits. And if you take that one step further in the pharmaceutical industry, that means it’s really about selling as much drug as you can, at the highest possible price, for the most patients, for the longest duration.”
Canada’s approach has saved significant funds, though experts like health law professor Matthew Herder consider it merely a “Band Aid solution.” He argues the country should target root causes by demanding lower initial list prices. Research suggests global savings of $5 billion US by 2040 could be achieved if lung cancer patients received weight-based dosing instead of Merck’s fixed recommendation.
The financial pressure extends beyond Keytruda itself. Between 2010 and 2019, cancer medicine sales in Canada tripled from $1.3 billion to $3.9 billion. A 2024 Ontario study revealed cancer drug spending rose from $500 million in 2012 to $1.7 billion by 2022, increasing at 15% annually—far outpacing the province’s 3-7% annual health budget growth.
Difficult Choices on the Horizon
The accelerating costs of breakthrough cancer therapies force society to confront uncomfortable questions about resource allocation. As Scott Gavura of Ontario Health acknowledges, “You need to have all the other pieces within the system for patients to benefit from that therapy.” This reality means every dollar spent on expensive drugs like Keytruda potentially displaces other vital health services.
Dr. Booth, who treated Lake, emphasises that these discussions aren’t about diminishing patient value. “Delivering a treatment that has such a radical impact on a patient’s life is one of the things that drew all of us into oncology,” he says. “We want to see more effective treatments like this developed — and be able to have a health system be able to pay for them.”
The challenge lies in balancing compassionate care with fiscal responsibility. Lake’s story exemplifies both the promise and the problem: a man who defied his prognosis through innovative treatment, yet whose care cost nearly half a million dollars before discounts. His wife Shari’s simple response captures the moral complexity: “He’s worth it.”
Yet when multiplied across thousands of patients nationwide, these costs threaten to undermine the very foundations of universal health care. The system must find sustainable ways to deliver life-extending treatments without compromising access to other essential services. The question isn’t whether breakthrough medicines deserve funding—it’s how society chooses to pay for them.
Canada’s approach with Keytruda demonstrates that challenging pharmaceutical industry norms can yield both clinical and financial benefits. However, the broader systemic issues remain unresolved. Until list prices are addressed at their source, each new breakthrough drug will likely trigger similar budgetary crises, forcing ever-greater trade-offs between saving lives and sustaining health care systems.
Why it Matters
The Keytruda saga illuminates a fundamental crisis in modern health policy: how democratic societies finance medical breakthroughs without bankrupting their institutions. This isn’t merely a Canadian story—it’s a harbinger of what awaits every nation embracing revolutionary therapies. As cancer transforms from a death sentence to a manageable chronic condition, the economic models supporting health care must evolve. The stakes extend beyond budgets; they encompass whether societies can sustain the promise of medical innovation while preserving equitable access for all patients. Canada’s weight-based dosing experiment offers hope, but the real solution requires transparency in pharmaceutical pricing and a fundamental rethinking of how societies value and finance life-saving medicines.
